Report cover image

Pulmonary Hypertension Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

Publisher BIS Research
Published Dec 17, 2025
SKU # BIS20659263

Description

Market Overview

The global pulmonary hypertension market is driven by the increasing prevalence of chronic conditions such as connective tissue diseases, congenital heart disease, and chronic obstructive pulmonary disease (COPD), which are major risk factors for pulmonary hypertension. Advances in targeted therapies, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors (PDE-5 inhibitors), and prostacyclin analogs, have improved patient outcomes by managing symptoms and slowing disease progression. The market is expanding with the approval of new biologics and combination therapies aimed at improving long-term management of pulmonary hypertension. However, challenges such as high treatment costs, delayed diagnosis, and the need for personalized care remain. The increasing awareness, early detection, and improved healthcare infrastructure in emerging markets will provide significant growth opportunities in the coming years.

Impact

Increasing demand for pulmonary hypertension therapies is anticipated to support the growth of the global pulmonary hypertension market during the forecast period 2025-2035.
The global pulmonary hypertension market is expected to grow at a significant rate due to advancements in treatment, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Demand – Drivers and Limitations

The following are the drivers for the global pulmonary hypertension market:

Growing prevalence of pulmonary hypertension and underlying conditions: Higher incidence of connective tissue disorders, congenital heart disease, and ageing populations globally drives demand for pulmonary hypertension therapies.
Advances in targeted therapies and combination regimens: New drugs including ERAs, PDE‑5 inhibitors, soluble guanylate cyclase stimulators and prostacyclin analogues have improved clinical outcomes, encouraging broader diagnosis and treatment.
Improved diagnostic capabilities and screening programs: Enhanced imaging, right‑heart catheterization access and awareness campaigns are boosting early detection of pulmonary hypertension, translating into higher treatment uptake and market expansion.

The global pulmonary hypertension market is expected to face some limitations too, due to the following challenges:

High cost of therapy and limited affordability: Many pulmonary hypertension treatments are high cost and require specialist administration, making access challenging in low‑ and middle‑income regions and limiting market growth.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report provides insights into emerging therapies, such as biologic treatments and novel combination therapies, helping organizations align their R&D with the evolving market needs. It also highlights regulatory trends and patient management practices, guiding innovation to address disease progression and adherence issues.

Competitive Strategy: The report outlines the competitive landscape, focusing on market players. It offers actionable insights into market share dynamics, pricing strategies, and clinical differentiation, enabling organizations to identify opportunities for collaboration, licensing, and regional market expansion.

Key Market Players and Competition Synopsis

Key players in the global pulmonary hypertension market offering effective treatment options for pulmonary hypertension. The competitive landscape is shaped by the need for combination therapies, personalized treatment approaches, and improved patient compliance. Companies are also focusing on expanding indications, global market access, and innovative delivery systems to maintain their leadership.

Some of the prominent names established in this market are:

Johnson & Johnson
Bayer AG
Lupin
United Therapeutics Corporation
GSK

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

Executive Summary
Scope of Study
Research Methodology
1. Global Pulmonary Hypertension Market: Industry Outlook
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Pulmonary Hypertension Market (By Region), $Million, 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Pulmonary Hypertension Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Pulmonary Hypertension Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Pulmonary Hypertension Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Pulmonary Hypertension Market - Competitive Landscape and Company Profiles
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Viatris Specialty LLC
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Johnson & Johnson
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Bayer AG
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 United Therapeutics Corporation
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Gilead Sciences, Inc.
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers/End Users
3.2.5.4 Analyst View
3.2.6 Lupin
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers/End Users
3.2.6.4 Analyst View
3.2.7 GSK plc
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers/End Users
3.2.7.4 Analyst View
3.2.8 Others
4. Research Methodology
List of Figures
Figure: Pulmonary Hypertension Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Pulmonary Hypertension Market, 2024 and 2035
Figure: Global Pulmonary Hypertension Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Europe Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Asia-Pacific Pulmonary Hypertension Market, $Million, 2024-2035
Figure: Rest-of-the-World Pulmonary Hypertension Market, $Million, 2024-2035
List of Tables
Table: Market Snapshot
Table: Market Dynamics
Table: Global Pulmonary Hypertension Market (by Region), $Million, 2024-2035

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us